[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Laitman CJ: DES exposure and the aging woman: mothers and daughters. Curr Womens Health Rep; 2002 Oct;2(5):390-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1971, the US Food and Drug Administration contraindicated its use in pregnancy when DES was associated with the development of vaginal clear cell adenocarcinoma (CCA) in daughters exposed in utero.
  • In daughters whose mothers took DES during pregnancy, the drug has been associated with congenital malformations of the reproductive tract, fertility problems, a possible increased risk of cervical carcinoma in situ, and a presumed lifetime risk of vaginal and cervical CCA.
  • DES mothers have an increased risk of breast cancer (RR = 1.3).
  • DES sons have an increased prevalence of urogenital anomalies, and a possible increased risk of testicular cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Breast Neoplasms / chemically induced. Carcinoma in Situ / chemically induced. Estrogen Replacement Therapy. Female. Genitalia, Female / abnormalities. Humans. Mothers. Nuclear Family. Pregnancy. Pregnancy Complications / prevention & control. Pregnancy, High-Risk. Risk Factors. Uterine Cervical Neoplasms / chemically induced. Vaginal Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12215312.001).
  • [ISSN] 1534-5874
  • [Journal-full-title] Current women's health reports
  • [ISO-abbreviation] Curr Womens Health Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


2. Swan SH: Intrauterine exposure to diethylstilbestrol: long-term effects in humans. APMIS; 2000 Dec;108(12):793-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vaginal clear cell adenocarcinoma (CCAC), the most severe consequence of prenatal exposure to DES, affected only 0.1% of exposed females, while the far more prevalent teratogenic and reproductive effects of DES were only discovered when DES daughter were screened for CCAC.
  • Initial studies, conducted before most DES daughters had tried to conceive, examined vaginal cancer and vaginal, cervical and uterine abnormalities.
  • While most DES daughters can eventually experience a live birth, this is less likely in women with genital tract abnormalities, in whom there is a two-thirds chance that each pregnancy will be unsuccessful.
  • [MeSH-major] Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Pregnancy Complications / drug therapy. Prenatal Exposure Delayed Effects
  • [MeSH-minor] Abnormalities, Drug-Induced / epidemiology. Adenocarcinoma, Clear Cell / chemically induced. Administration, Intravaginal. Cervix Uteri / abnormalities. Female. Follow-Up Studies. Gestational Age. Humans. Infant, Newborn. Infant, Newborn, Diseases / chemically induced. Infant, Newborn, Diseases / epidemiology. Male. Pregnancy. Risk. Teratoma / chemically induced. Testicular Neoplasms / chemically induced. United States / epidemiology. Uterus / abnormalities. Vagina / abnormalities. Vaginal Diseases / chemically induced. Vaginal Diseases / epidemiology. Vaginal Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11252812.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 75
  •  go-up   go-down


3. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res; 2005 May-Jun;25(3c):2399-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Caffeine / pharmacology. Carcinoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


Advertisement
4. Deligdisch L, Pénault-Llorca F, Schlosshauer P, Altchek A, Peiretti M, Nezhat F: Stage I ovarian carcinoma: different clinical pathologic patterns. Fertil Steril; 2007 Oct;88(4):906-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTING: Mount Sinai School of Medicine, New York and the Centre Jean Perrin, Clermont Ferrand, France.
  • PATIENT(S): Seventy-six consecutive cases of Fédération Internationale de Gynécologie et d'Obstétrique stage I ovarian carcinoma.
  • RESULT(S): Twenty-two cases (29%) were serous papillary carcinomas and 54 were nonserous carcinomas (71%) (40 endometrioid, 10 clear cell, and 4 mixed endometrioid and clear cell carcinomas).
  • Most patients with serous papillary carcinoma presented with asymptomatic pelvic masses; patients with nonserous carcinomas presented with pelvic pain or abnormal vaginal bleeding with or without pelvic mass.
  • CONCLUSION(S): Over two thirds of stage I ovarian carcinomas were nonserous, and were diagnosed because of associated symptoms: pelvic pain with endometriosis and/or adnexal masses, or vaginal bleeding from endometrial pathology.
  • Serous papillary carcinomas were often asymptomatic and diagnosed during follow-up evaluations in breast cancer patients.
  • The risk of ovarian and endometrial malignancy should be taken into consideration during evaluation of patients with endometriosis and breast cancer histories.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920404.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


5. Fickling D: Australia recognises cancer risk for "DES daughters". Lancet; 2004 Jun 19;363(9426):2059
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Australia recognises cancer risk for "DES daughters".
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemically induced. Carcinogens. Diethylstilbestrol / adverse effects. Prenatal Exposure Delayed Effects. Vaginal Neoplasms / chemically induced
  • [MeSH-minor] Australia. Breast Neoplasms / chemically induced. Drug Information Services. Female. Humans. Pregnancy. Risk Factors. Uterine Cervical Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15209080.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


6. Schrager S, Potter BE: Diethylstilbestrol exposure. Am Fam Physician; 2004 May 15;69(10):2395-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Food and Drug Administration issued a warning about the use of diethylstilbestrol during pregnancy after a relationship between exposure to this synthetic estrogen and the development of clear cell adenocarcinoma of the vagina and cervix was found in young women whose mothers had taken diethylstilbestrol while they were pregnant.
  • Women who took diethylstilbestrol during pregnancy have a slightly higher risk of breast cancer than the general population and therefore should be encouraged to have regular mammography.
  • Recommendations for gynecologic examinations include vaginal and cervical digital palpation, which may provide the only evidence of clear cell adenocarcinoma.
  • If the initial colposcopic examination is normal, annual cervical and vaginal cytology is recommended.
  • The male offspring of women who took diethylstilbestrol during pregnancy have an increased incidence of genital abnormalities and a possibly increased risk of prostate and testicular cancer.
  • Routine prostate cancer screening and testicular self-examination should be encouraged.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15168959.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 37
  •  go-up   go-down


7. Parker R, Lanvin D, Gilks B, Miller D: Spontaneous regression of stage IV clear cell carcinoma of the endometrium in a patient with essential thrombocytosis. Gynecol Oncol; 2001 Aug;82(2):395-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of stage IV clear cell carcinoma of the endometrium in a patient with essential thrombocytosis.
  • OBJECTIVE: The aim of this study was to document a case of advanced stage clear cell carcinoma of the endometrium which underwent spontaneous regression (SR) and comment on the possible contribution of the patient's thrombocytosis.
  • CASE REPORT: A 73-year-old woman with essential thrombocytosis presented with vaginal bleeding.
  • Biopsy of the subumbilical mass revealed adenocarcinoma, and endometrial curettage revealed extensively necrotic clear cell endometrial carcinoma.
  • Interestingly, her platelet-lowering agent (hydroxyurea) was discontinued shortly before, and her platelet count was significantly elevated at the time of her presentation with endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / blood. Endometrial Neoplasms / blood. Neoplasm Regression, Spontaneous. Thrombocytosis / blood

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11531303.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Dasanu CA, Herzog TJ: Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview. Medscape J Med; 2009;11(1):6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview.
  • BACKGROUND: Clear cell adenocarcinoma of the vagina and cervix were previously shown to be tumors occurring in female offspring exposed prenatally to diethylstilbestrol.
  • This report describes the first clinical case of clear cell adenocarcinoma of the ovary linked to early diethylstilbestrol exposure in utero.
  • She underwent surgery and staging that revealed clear cell adenocarcinoma confined to the left ovary.
  • CONCLUSION: Our case is consistent with clear cell adenocarcinoma, probably related to diethylstilbestrol exposure in utero.
  • It reinforces the need for continued vigilance in individuals prenatally exposed to this drug.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemically induced. Diethylstilbestrol / adverse effects. Ovarian Neoplasms / chemically induced. Prenatal Exposure Delayed Effects / chemically induced

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):837-45 [11714112.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1615-24 [7370920.001]
  • [Cites] Biol Reprod. 1983 Apr;28(3):735-44 [6850046.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):85-96 [2469661.001]
  • [Cites] Epidemiology. 2008 Mar;19(2):251-7 [18223485.001]
  • [Cites] Semin Diagn Pathol. 1997 Nov;14(4):233-9 [9383823.001]
  • [Cites] Obstet Gynecol. 2005 Jan;105(1):167-73 [15625159.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):356-60 [17390375.001]
  • [Cites] Semin Surg Oncol. 1990;6(6):343-6 [2263810.001]
  • (PMID = 19295927.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  • [Other-IDs] NLM/ PMC2654676
  •  go-up   go-down


9. Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP: Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adjuvant vaginal brachytherapy (VB) was delivered in 10, chemotherapy in 5, and hormonal therapy in 7 patients.
  • Of the 7 pelvic failures, 4 were vaginal (3 vaginal only).
  • Patients treated with VB had a trend to a lower vaginal recurrence rate (0/10 vs. 4/20, p = 0.12) than those not receiving VB.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Hysterectomy. Ovariectomy. Radiotherapy, Adjuvant
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Chicago / epidemiology. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / radiotherapy. Cystadenocarcinoma, Papillary / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483324.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


10. Fujiwara K, Suzuki S, Yoden E, Ishikawa H, Imajo Y, Kohno I: Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. Int J Gynecol Cancer; 2002 May-Jun;12(3):250-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.
  • The purpose of this paper is to prospectively evaluate the effects of local radiation therapy upon localized ovarian cancer following chemotherapy.
  • Forty-four disease sites, including the lymph nodes, vaginal cuff, pelvis, abdomen, subcutaneous regions, and the brain were irradiated.
  • We conclude that local radiation therapy may be one of the treatment options for relapsed or refractory but localized ovarian cancer, particularly when the tumor is small and/or located in the lymph nodes, even when patients had no symptoms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Neoplasm Recurrence, Local / radiotherapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiotherapy. Adult. Aged. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radiotherapy. Combined Modality Therapy. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radiotherapy. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms, Glandular and Epithelial / drug therapy. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / radiotherapy. Pilot Projects. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060445.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Pinto AB, Gopal M, Herzog TJ, Pfeifer JD, Williams DB: Successful in vitro fertilization pregnancy after conservative management of endometrial cancer. Fertil Steril; 2001 Oct;76(4):826-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful in vitro fertilization pregnancy after conservative management of endometrial cancer.
  • OBJECTIVE: To report a successful IVF pregnancy in an infertile couple after conservative treatment of endometrial cancer.
  • MAIN OUTCOME MEASURE(S): Successful pregnancy after conservative management of endometrial cancer.
  • INTERVENTION(S): Grade 1 endometrial adenocarcinoma diagnosed at hysteroscopy, followed by dilatation and curettage (D&C).
  • Laparoscopic-assisted vaginal hysterectomy and bilateral salpingo-oophorectomy was then done.
  • No residual endometrial cancer was evident in the hysterectomy specimen, but a 1.1-cm cystic mixed endometrioid and clear cell-type adenocarcinoma was discovered in the left ovary.
  • CONCLUSION(S): In carefully chosen situations, deferring surgery in infertile patients with endometrial cancer may be a viable option permitting subsequent successful pregnancy.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Fertilization in Vitro. Pregnancy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Hysterectomy, Vaginal. Neoplasms, Second Primary / drug therapy. Ovarian Neoplasms / drug therapy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11591422.001).
  • [ISSN] 0015-0282
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Keller C, Nanda R, Shannon RL, Amit A, Kaplan AL: Concurrent primaries of vaginal clear cell adenocarcinoma and endometrial adenocarcinoma in a 39-year old woman with in utero diethylstilbestrol exposure. Int J Gynecol Cancer; 2001 May-Jun;11(3):247-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent primaries of vaginal clear cell adenocarcinoma and endometrial adenocarcinoma in a 39-year old woman with in utero diethylstilbestrol exposure.
  • In 1971 the US Food and Drug Administration proscribed its use for pregnancy support secondary to its association with clear cell adenocarcinoma of the vagina.
  • Several studies in animal models demonstrated an association with endometrial cancer among offspring following in utero DES exposure.
  • To date, there is only one case report of endometrial cancer in women exposed to DES in utero.
  • We present the first case, to our knowledge, of a woman exposed to DES in utero who presented with double primaries of clear cell cancer of the vagina concomitant with endometrial cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Carcinogens / adverse effects. Diethylstilbestrol / adverse effects. Endometrial Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Diagnosis, Differential. Female. Humans. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437935.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


13. Sato K, Fukata H, Kogo Y, Ohgane J, Shiota K, Mori C: Neonatal exposure to diethylstilbestrol alters expression of DNA methyltransferases and methylation of genomic DNA in the mouse uterus. Endocr J; 2009;56(1):131-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perinatal exposure to diethylstilbestrol (DES) can have numerous adverse effects on the reproductive organs later in life, such as vaginal clear-cell adenocarcinoma.
  • [MeSH-major] DNA (Cytosine-5-)-Methyltransferase / genetics. DNA Methylation / drug effects. Diethylstilbestrol / pharmacology. Gene Expression Regulation, Enzymologic / drug effects. Uterus / drug effects
  • [MeSH-minor] Age Factors. Animals. Animals, Newborn. Body Weight / drug effects. Drug Evaluation, Preclinical. Estrogens, Non-Steroidal / pharmacology. Female. Genome / drug effects. Mice. Mice, Inbred C57BL. Organ Size / drug effects. Pregnancy. Transcription Factors / genetics. Transcription Factors / metabolism

  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997445.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 0 / Transcription Factors; 731DCA35BT / Diethylstilbestrol; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase
  •  go-up   go-down


14. Rosen F: DES up close. Nurse Pract; 2003 Jul;28(7 Pt 1):34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Abnormalities, Drug-Induced / diagnosis. Abnormalities, Drug-Induced / etiology. Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Prenatal Exposure Delayed Effects
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / diagnosis. Female. Genitalia, Female / abnormalities. Humans. Medical Errors / legislation & jurisprudence. Medical History Taking / methods. Patient Education as Topic / methods. Physical Examination / methods. Pregnancy. Vaginal Neoplasms / chemically induced. Vaginal Neoplasms / diagnosis. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Pregnancy and Medicines.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12861093.001).
  • [ISSN] 0361-1817
  • [Journal-full-title] The Nurse practitioner
  • [ISO-abbreviation] Nurse Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


15. Lauver D, Nelles KK, Hanson K: The health effects of diethylstilbestrol revisited. J Obstet Gynecol Neonatal Nurs; 2005 Jul-Aug;34(4):494-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The health effects of diethylstilbestrol revisited.
  • Although diethylstilbestrol has not been prescribed commonly for more than 25 years, its effects on the health of exposed persons are still important.
  • In this article, we summarize current information about the major health effects of diethylstilbestrol exposure and delineate implications for nurses.
  • Nurses can help to identify persons at risk from prior diethylstilbestrol exposure, facilitate comprehensive assessments of persons exposed to diethylstilbestrol, and share current information about diethylstilbestrol.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020417.001).
  • [ISSN] 0884-2175
  • [Journal-full-title] Journal of obstetric, gynecologic, and neonatal nursing : JOGNN
  • [ISO-abbreviation] J Obstet Gynecol Neonatal Nurs
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 13
  •  go-up   go-down


16. Anderson LM, Diwan BA, Fear NT, Roman E: Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models. Environ Health Perspect; 2000 Jun;108 Suppl 3:573-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models.
  • In humans, cancer may be caused by genetics and environmental exposures; however, in the majority of instances the identification of the critical time window of exposure is problematic.
  • Agents definitely related to cancer in children, and adulthood if exposure occurs in utero, include: maternal exposure to ionizing radiation during pregnancy and childhood leukemia and certain other cancers, and maternal use of diethylstilbestrol during pregnancy and clear-cell adenocarcinoma of the vagina of their daughters.
  • The list of environmental exposures that occur during the perinatal/postnatal period with potential to increase the risk of cancer is lengthening, but evidence available to date is inconsistent and inconclusive.
  • Mechanistic factors include the number of cells at risk, the rate of cell division, the development of differentiated characteristics including the ability to activate and detoxify carcinogens, the presence of stem cells, and possibly others.
  • [MeSH-major] Cell Transformation, Neoplastic. Neoplasms / etiology. Xenobiotics / adverse effects
  • [MeSH-minor] Adult. Animals. Child. Disease Models, Animal. Environmental Exposure. Epidemiologic Studies. Female. Gonads / drug effects. Gonads / embryology. Humans. Neoplasms, Experimental / etiology. Pregnancy. Radiation, Ionizing. Risk Assessment

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1993 May 27;363(6427):358-60 [8497319.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):97-9 [7848376.001]
  • [Cites] Mutat Res. 1993 Jun;287(2):207-16 [7685480.001]
  • [Cites] BMJ. 1993 Jul 10;307(6896):89-91 [8343734.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):357-63 [8347491.001]
  • [Cites] Gan. 1981 Aug;72(4):569-77 [7308669.001]
  • [Cites] Int J Cancer. 1981 Oct 15;28(4):475-8 [7309291.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Nov 15;161(1):82-99 [10558926.001]
  • [Cites] J Natl Cancer Inst. 1966 Oct;37(4):409-20 [5950982.001]
  • [Cites] Nature. 1968 Apr 20;218(5138):280-1 [4296763.001]
  • [Cites] Cancer Res. 1968 Apr;28(4):727-38 [4968106.001]
  • [Cites] Z Krebsforsch. 1968;71(4):320-60 [4237278.001]
  • [Cites] Int J Cancer. 1969 Mar 15;4(2):166-78 [4899788.001]
  • [Cites] Int J Cancer. 1969 Mar 15;4(2):219-25 [5347285.001]
  • [Cites] N Engl J Med. 1971 Apr 15;284(15):878-81 [5549830.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Gan. 1972 Dec;63(6):731-42 [4346083.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):313-24 [4347033.001]
  • [Cites] Br Med J. 1973 Mar 17;1(5854):675 [4692717.001]
  • [Cites] Gan. 1973 Feb;64(1):29-40 [4718408.001]
  • [Cites] Acta Radiol Ther Phys Biol. 1973 Jun;12(3):201-8 [4749175.001]
  • [Cites] Cancer Res. 1974 Apr;34(4):764-70 [4360839.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Mar;71(3):639-43 [4522778.001]
  • [Cites] Cancer Res. 1974 Sep;34(9):2217-31 [4858678.001]
  • [Cites] Cancer Res. 1974 Dec;34(12):3363-72 [4429956.001]
  • [Cites] Cancer Res. 1974 Dec;34(12):3373-8 [4371957.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1974;81(3-4):269-72 [4279523.001]
  • [Cites] Cancer Res. 1975 Jan;35(1):264-6 [1167346.001]
  • [Cites] Cancer Res. 1975 Jul;35(7):1637-42 [1169110.001]
  • [Cites] J Natl Cancer Inst. 1975 Jun;54(6):1439-48 [1169326.001]
  • [Cites] IARC Sci Publ. 1989;(96):93-103 [2680958.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] Mutat Res. 1996 Apr 2;362(3):237-48 [8637502.001]
  • [Cites] BMJ. 1998 Jan 17;316(7126):178-84 [9468681.001]
  • [Cites] BMJ. 1998 Jan 17;316(7126):189-93 [9468683.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):825-9 [9514065.001]
  • [Cites] Br Med Bull. 1998;54(1):95-103 [9604435.001]
  • [Cites] J Natl Cancer Inst. 1975 Sep;55(3):681-3 [1159845.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1975 Oct 27;84(2):207-15 [171871.001]
  • [Cites] J Natl Cancer Inst. 1975 Nov;55(5):1165-9 [1206742.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1976 May 3;86(1):69-75 [132030.001]
  • [Cites] Int J Cancer. 1976 Jun 15;17(6):742-7 [988851.001]
  • [Cites] Naturwissenschaften. 1976 Oct;63(10):487-8 [980118.001]
  • [Cites] J Natl Cancer Inst. 1976 Oct;57(4):821-5 [1003530.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2897-904 [6850601.001]
  • [Cites] Chem Biol Interact. 1983 Apr-May;44(1-2):63-77 [6850927.001]
  • [Cites] Int J Cancer. 1983 Jun 15;31(6):779-84 [6862687.001]
  • [Cites] Mutat Res. 1983 Jul;121(1):59-65 [6866003.001]
  • [Cites] Cancer Res. 1983 Sep;43(9):4271-4 [6409402.001]
  • [Cites] Environ Mutagen. 1984;6(1):33-40 [6692799.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(1):30-5 [6746713.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(1):56-9 [6746716.001]
  • [Cites] Prog Exp Tumor Res. 1984;27:1-16 [6385121.001]
  • [Cites] Am J Epidemiol. 1985 Jan;121(1):49-56 [3155484.001]
  • [Cites] Cancer Lett. 1985 May;27(1):81-90 [2408741.001]
  • [Cites] Carcinogenesis. 1985 Sep;6(9):1389-93 [4028336.001]
  • [Cites] Int J Epidemiol. 1985 Dec;14(4):555-9 [3866751.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):4135-8 [3731080.001]
  • [Cites] Q Rev Biol. 1986 Sep;61(3):339-74 [3532167.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):348-52 [3791225.001]
  • [Cites] Br J Cancer. 1987 May;55(5):571-7 [3606949.001]
  • [Cites] Cancer Res. 1987 Oct 1;47(19):5112-5 [3621196.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):331-8 [3478072.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):379-86 [3335010.001]
  • [Cites] Carcinogenesis. 1988 Nov;9(11):1931-4 [3180332.001]
  • [Cites] Chem Biol Interact. 1988;68(3-4):259-71 [3214887.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1676-81 [2538231.001]
  • [Cites] Paediatr Perinat Epidemiol. 1989 Jan;3(1):66-94 [2652101.001]
  • [Cites] Cancer Res. 1989 Jul 1;49(13):3620-6 [2731179.001]
  • [Cites] Fundam Appl Toxicol. 1989 Apr;12(3):604-20 [2731672.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):975-8 [2732008.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3770-5 [2736518.001]
  • [Cites] Cancer Res. 1989 Oct 15;49(20):5730-5 [2790788.001]
  • [Cites] IARC Sci Publ. 1989;(96):1-15 [2680943.001]
  • [Cites] IARC Sci Publ. 1989;(96):17-34 [2553598.001]
  • [Cites] IARC Sci Publ. 1989;(96):335-48 [2680951.001]
  • [Cites] Lancet. 1991 Oct 12;338(8772):955 [1681306.001]
  • [Cites] J Natl Cancer Inst. 1991 Nov 20;83(22):1643-50 [1749017.001]
  • [Cites] BMJ. 1990 Feb 17;300(6722):423-9 [2107892.001]
  • [Cites] Mutat Res. 1990 Apr;229(2):231-7 [2320033.001]
  • [Cites] Mutat Res. 1990 Apr;229(2):239-46 [2320034.001]
  • [Cites] Am J Hum Genet. 1990 Jul;47(1):155-60 [1971994.001]
  • [Cites] BMJ. 1990 May 12;300(6734):1229-33 [2354290.001]
  • [Cites] Carcinogenesis. 1992 Aug;13(8):1351-7 [1499087.001]
  • [Cites] J Radiat Res. 1991 Dec;32 Suppl 2:64-72 [1823368.001]
  • [Cites] J Radiat Res. 1991 Dec;32 Suppl 2:73-85 [1823369.001]
  • [Cites] J Radiat Res. 1991 Dec;32 Suppl 2:86-103 [1823370.001]
  • [Cites] BMJ. 1992 Aug 8;305(6849):341-6 [1392886.001]
  • [Cites] BMJ. 1992 Sep 19;305(6855):715 [1393138.001]
  • [Cites] Cancer Res. 1992 Nov 1;52(21):6125-8 [1327525.001]
  • [Cites] Lancet. 1992 Oct 24;340(8826):1015-8 [1357410.001]
  • [Cites] Am J Epidemiol. 1992 Nov 1;136(9):1115-21 [1334366.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1546-9 [8453621.001]
  • [Cites] BMJ. 1993 Mar 6;306(6878):615-21 [8461811.001]
  • [Cites] Am J Epidemiol. 1993 Mar 15;137(6):629-38 [8470664.001]
  • [Cites] Am J Epidemiol. 1993 Mar 15;137(6):639-44 [8470665.001]
  • [Cites] J Med Genet. 1991 Apr;28(4):217-23 [1677423.001]
  • [Cites] Carcinogenesis. 1991 Aug;12(8):1409-15 [1860162.001]
  • [Cites] Cancer Surv. 1990;9(3):395-416 [2101719.001]
  • [Cites] Cancer Surv. 1990;9(3):529-54 [2101724.001]
  • [Cites] Nature. 1991 Oct 3;353(6343):431-4 [1654525.001]
  • [Cites] Nat Genet. 1993 Jun;4(2):110-3 [8348145.001]
  • [Cites] Carcinogenesis. 1993 Aug;14(8):1545-8 [8353839.001]
  • [Cites] N Engl J Med. 1993 Sep 23;329(13):905-8 [8361503.001]
  • [Cites] Mutat Res. 1993 Sep;319(1):71-9 [7690461.001]
  • [Cites] Carcinogenesis. 1993 Sep;14(9):1805-13 [8403203.001]
  • [Cites] Br J Ophthalmol. 1993 Oct;77(10):662-72 [8218038.001]
  • [Cites] Med Pediatr Oncol. 1994;22(1):33-8 [8232078.001]
  • [Cites] BMJ. 1993 Oct 16;307(6910):959-66 [8241906.001]
  • [Cites] BMJ. 1994 Apr 2;308(6933):895-6 [8173370.001]
  • [Cites] Jpn J Cancer Res. 1994 May;85(5):443-54 [8014100.001]
  • [Cites] Hum Genet. 1994 Jul;94(1):31-8 [8034292.001]
  • [Cites] N Engl J Med. 1994 Sep 1;331(9):586-90 [8047084.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):969-72 [7947106.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1678-80 [7966394.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):395-405 [8001010.001]
  • [Cites] BMJ. 1994 Dec 17;309(6969):1612-6 [7819936.001]
  • [Cites] Am J Epidemiol. 1995 Feb 1;141(3):210-7 [7840094.001]
  • [Cites] Mutat Res. 1995 Feb;316(3):139-45 [7862177.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1778-82 [7880605.001]
  • [Cites] Cancer Surv. 1994;19-20:493-517 [7534639.001]
  • [Cites] Int J Cancer. 1995 Apr 10;61(2):249-52 [7705955.001]
  • [Cites] Cancer Res. 1977 Jun;37(6):1822-8 [858142.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977 Nov 18;90(2):119-26 [145753.001]
  • [Cites] J Pediatr. 1978 Jun;92(6):925-9 [96239.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1978 May 31;91(2):157-64 [149439.001]
  • [Cites] Gan. 1978 Jun;69(3):451-2 [208909.001]
  • [Cites] Gan. 1978 Apr;69(2):167-77 [680461.001]
  • [Cites] Natl Cancer Inst Monogr. 1979 May;(51):117-22 [481573.001]
  • [Cites] Natl Cancer Inst Monogr. 1979 May;(51):123-58 [225667.001]
  • [Cites] Natl Cancer Inst Monogr. 1979 May;(51):219-26 [384262.001]
  • [Cites] Natl Cancer Inst Monogr. 1979 May;(51):227-31 [481575.001]
  • [Cites] Natl Cancer Inst Monogr. 1979 May;(51):239-50 [384263.001]
  • [Cites] J Toxicol Environ Health. 1979 Nov;5(6):1059-71 [119055.001]
  • [Cites] J Natl Cancer Inst. 1980 Sep;65(3):607-14 [6251304.001]
  • [Cites] J Cancer Res Clin Oncol. 1980;98(1):65-74 [7451554.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):3973-6 [7193510.001]
  • [Cites] J Cancer Res Clin Oncol. 1980;98(3):267-75 [6785280.001]
  • [Cites] Hum Genet. 1981;57(3):231-46 [6265341.001]
  • [Cites] J Natl Cancer Inst. 1981 Aug;67(2):461-6 [6790803.001]
  • [Cites] Proc Soc Exp Biol Med. 1964 Jun;116:265-8 [14189113.001]
  • [Cites] J Chronic Dis. 1965 Feb;18:113-32 [14258467.001]
  • [Cites] Carcinogenesis. 1981;2(11):1087-94 [6797749.001]
  • [Cites] Photochem Photobiol. 1982 Feb;35(2):181-5 [7063543.001]
  • [Cites] Cancer Res. 1982 May;42(5):2003-11 [7066910.001]
  • [Cites] Nature. 1982 Apr 8;296(5857):575-7 [7200193.001]
  • [Cites] Lancet. 1982 Jul 17;2(8290):152 [6123856.001]
  • [Cites] Lancet. 1996 Dec 7;348(9041):1542-6 [8950880.001]
  • [Cites] Blood. 1997 Jan 1;89(1):281-5 [8978302.001]
  • [Cites] Br J Cancer. 1997;75(1):134-8 [9000611.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] J Epidemiol Community Health. 1996 Dec;50(6):645-52 [9039384.001]
  • [Cites] Hum Reprod. 1996 Dec;11 Suppl 4:110-7; discussion 118-20 [9147114.001]
  • [Cites] Environ Health Perspect. 1997 Apr;105 Suppl 3:655-63 [9168010.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):939-47 [9214673.001]
  • [Cites] Br J Cancer. 1997;76(3):406-15 [9252212.001]
  • [Cites] Environ Mol Mutagen. 1997;30(3):254-9 [9366902.001]
  • [Cites] BMJ. 1997 Nov 8;315(7117):1181-8 [9393219.001]
  • [Cites] J Pediatr. 1997 Nov;131(5):666-70 [9403643.001]
  • [Cites] BMJ. 1998 Jan 17;316(7126):173-7 [9468680.001]
  • [Cites] Int J Cancer. 1992 Jan 2;50(1):131-5 [1728603.001]
  • [Cites] Clin Pediatr (Phila). 1991 Dec;30(12):676-81 [1764876.001]
  • [Cites] Carcinogenesis. 1992 Feb;13(2):145-51 [1740003.001]
  • [Cites] Leukemia. 1992;6 Suppl 1:1-4 [1548931.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1948-53 [1551123.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):778-88 [7717601.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 May;17(2):94-100 [7749772.001]
  • [Cites] Int J Radiat Biol. 1995 May;67(5):607-15 [7775836.001]
  • [Cites] Cancer Causes Control. 1995 May;6(3):240-56 [7612804.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):908-14 [7666480.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4479-85 [7671263.001]
  • [Cites] Int J Cancer. 1995 Sep 27;63(1):86-91 [7558458.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2023-8 [7554049.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):441-5 [7549797.001]
  • [Cites] Ann Epidemiol. 1995 Sep;5(5):354-9 [8653207.001]
  • [Cites] Int J Cancer. 1996 Jan 3;65(1):39-50 [8543394.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:7-12 [8549494.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:41-4 [8549487.001]
  • [Cites] Int J Radiat Biol. 1995 Dec;68(6):679-86 [8551111.001]
  • [Cites] Genet Epidemiol. 1995;12(5):467-74 [8557179.001]
  • [Cites] Eur J Cancer. 1995 Nov;31A(12):2028-34 [8562160.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103(11):1018-25 [8605850.001]
  • [Cites] Jpn J Cancer Res. 1996 Jan;87(1):51-7 [8609049.001]
  • [Cites] Int J Radiat Biol. 1996 Apr;69(4):487-92 [8627131.001]
  • [Cites] Epidemiol Rev. 1995;17(2):415-32 [8654519.001]
  • [Cites] BMJ. 1996 Jul 27;313(7051):199-203 [8696195.001]
  • [Cites] BMJ. 1996 Jul 27;313(7051):204-5 [8696197.001]
  • [Cites] Pharmacogenetics. 1995 Dec;5(6):364-72 [8747408.001]
  • [Cites] Cancer Causes Control. 1996 Sep;7(5):553-9 [8877054.001]
  • [Cites] J Cancer Res Clin Oncol. 1996;122(11):643-52 [8898973.001]
  • [Cites] Lancet. 1998 Aug 8;352(9126):452-3 [9708757.001]
  • [Cites] Mutat Res. 1998 Jul 17;403(1-2):1-12 [9726000.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1553-8 [9771924.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1655-63 [9771938.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1577-85 [9794235.001]
  • [Cites] J Pediatr. 1998 Nov;133(5):617-23 [9821417.001]
  • [Cites] Cancer Causes Control. 1998 Oct;9(5):475-86 [9934714.001]
  • [Cites] Carcinogenesis. 1999 Feb;20(2):325-32 [10069472.001]
  • [Cites] Ann Genet. 1999;42(1):11-5 [10214502.001]
  • [Cites] Acta Oncol. 1999;38 Suppl 12:1-103 [10225326.001]
  • [Cites] Teratog Carcinog Mutagen. 1999;19(2):87-103 [10332806.001]
  • [Cites] BMJ. 1999 May 29;318(7196):1443-50 [10346768.001]
  • [Cites] Mutat Res. 1999 Jun 1;427(1):47-58 [10354501.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):1092-7 [10362122.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Jul 15;158(2):161-76 [10406931.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Free Radic Biol Med. 1999 Jul;27(1-2):90-4 [10443924.001]
  • [Cites] Nutr Cancer. 1999;34(1):111-8 [10453449.001]
  • [Cites] Adv Pediatr. 1952 Jan;5:129-53 [14952375.001]
  • [Cites] Lancet. 1956 Sep 1;271(6940):447 [13358242.001]
  • [Cites] Br Med J. 1958 Jun 28;1(5086):1495-508 [13546604.001]
  • [Cites] Carcinogenesis. 1990 Aug;11(8):1367-72 [2387022.001]
  • [Cites] Br J Cancer. 1990 Jul;62(1):152-68 [2202420.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7129-33 [2224847.001]
  • [Cites] Radiat Res. 1990 Nov;124(2):227-34 [2247603.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7677-81 [2174729.001]
  • [Cites] Lancet. 1990 Dec 22-29;336(8730):1577 [1979385.001]
  • [Cites] Br J Cancer. 1990 Dec;62(6):996-9 [2257233.001]
  • [Cites] BMJ. 1991 Mar 23;302(6778):687-92 [2021742.001]
  • [Cites] Toxicol Pathol. 1991;19(1):35-46 [2047706.001]
  • [Cites] Exp Lung Res. 1991 Mar-Apr;17(2):169-79 [2050023.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3696-701 [2065325.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):993-9 [2069856.001]
  • [Cites] Cancer Lett. 1991 Jul 4;58(3):177-81 [1855194.001]
  • (PMID = 10852857.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Xenobiotics
  • [Number-of-references] 257
  • [Other-IDs] NLM/ PMC1637809
  •  go-up   go-down


17. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
  • PURPOSE: To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT).
  • Thirty-eight women (5.5%) had clear-cell tumors (18 clear-cell only, 8 clear-cell + adenocarcinoma, and 12 clear-cell + other unfavorable histologies [10 papillary serous, 1 uterine sarcoma, 1 both]).
  • FIGO stages were as follows: 3 IA, 4 IB, 5 IC, 4 IIA, 6 IIB, 8 IIIA, 2 IIIB, 3 IIIC, and 6 IV.
  • Adjuvant therapies included the following: 5 none, 22 RT (13 pelvic RT, 2 vaginal brachytherapy, 7 both), 11 chemotherapy (8 alone, 3 after pelvic RT), and 3 hormones.
  • Patients with clear +/- adenocarcinoma histology had a similar 5-year disease-free survival (38.8% vs. 38.7%, p = 0.95) compared with those with clear-cell + other unfavorable histologies.
  • Eight failed in the pelvis (5 vagina, 3 lateral pelvis).
  • Only 1 (2%) patient developed an isolated abdominal failure (This patient had a mixed clear-cell/papillary serous tumor).
  • Of the 26 women with clear-cell +/- adenocarcinoma histology, only 1 (3.8%) relapsed in the abdomen.
  • CONCLUSION: Clear-cell carcinoma comprises a small percentage of endometrial cancers, frequently presents as a mixed histology, and has a poor overall outcome.
  • Unlike papillary serous tumors, clear-cell carcinoma does not seem to have a high propensity for abdominal failure.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Radiotherapy, Adjuvant
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pelvic Neoplasms / secondary. Prognosis. Sarcoma / pathology. Treatment Failure. Treatment Outcome. Uterine Neoplasms / pathology. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654437.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 30
  •  go-up   go-down


18. Martínez-Monge R, Nagore G, Cambeiro M, Garrán C, Villafranca E, Jurado M: Intravaginal 1-week high-dose-rate brachytherapy alone for Stages I-II endometrial cancer. Brachytherapy; 2007 Jul-Sep;6(3):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravaginal 1-week high-dose-rate brachytherapy alone for Stages I-II endometrial cancer.
  • METHODS AND MATERIALS: From December 1999 to February 2005, 50 patients with International federation of gynecology and obstetrics Stages IA-IIB endometrioid endometrial adenocarcinoma were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by postoperative HDR brachytherapy alone.
  • No vaginal or pelvic recurrences have been observed.
  • CONCLUSIONS: The results reported in this study are in agreement with previous reports of postoperative HDR brachytherapy alone in early-stage endometrial cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / radiotherapy. Brachytherapy / methods. Carcinoma, Adenosquamous / radiotherapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Feasibility Studies. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Staging / methods. Ovariectomy / methods. Postoperative Care / methods. Radiotherapy, Adjuvant / methods. Retrospective Studies. Treatment Outcome. Vagina

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681240.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Koizumi T, Bando S, Kanda K, Inai T: [Two cases of primary female urethral cancer]. Nihon Hinyokika Gakkai Zasshi; 2007 Sep;98(6):790-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of primary female urethral cancer].
  • Herein, we report two cases of female urethral cancer.
  • Histopathological examination of transperineal biopsy specimens from both patients suggested clear cell adenocarcinoma in case 1 and squamous cell carcinoma in case 2.
  • Both cases underwent total urethrectomy with partial resection of the vaginal wall and cystostomy urinary diversion.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Urethral cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929463.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


20. Takai Y, Tsutsumi O: [Synthetic estrogen as a endocrine disruptor--diethylstilbestrol and oral contraceptives]. Nihon Rinsho; 2000 Dec;58(12):2409-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral contraceptives containing ethynylestradiol, a synthetic estrogen, have been suspected to have adverse environmental effects since prenatal exposure to diethylstilbestrol, another synthetic estrogen, was reported to be associated with clear cell adenocarcinoma of the vagina in female offspring.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Animals. Female. Humans. Reproduction / drug effects. Vaginal Neoplasms / chemically induced

  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11187729.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal; 0 / Environmental Pollutants; 0 / Estradiol Congeners; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 27
  •  go-up   go-down






Advertisement